Transcatheter injection-induced changes in human bone marrow-derived mesenchymal stem cells.

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Biotechnology

Background:

• Human mesenchymal stem cells (hMSC) are used for myocardial dysfunction treatment via direct intramyocardial injection.
• The impact of needle transit on hMSC functionality is not well understood, despite its critical role in delivery.
• Assessing hMSC function beyond viability is crucial for effective cell-based therapies.

Purpose of the Study:

• To evaluate the effects of needle passage on hMSC clonogenicity, gene expression, and cytokine secretion.
• To compare hMSC function after injection through a 26-gauge Nitinol needle at different flow rates versus controls.

Main Methods:

• hMSCs (20 million/ml) were injected through a 26-gauge Nitinol needle at 400 and 1600 µl/min.
• Evaluated cell viability, colony-forming unit (CFU) formation, gene expression, and cytokine secretion.
• Compared injected hMSCs to non-injected control samples at baseline and 72 hours post-injection.

Main Results:

• hMSC viability and CFU formation were not significantly altered by injection or flow rate.
• Transient, marginal alterations in gene expression for certain cytokines (bFGF, SDF-1, SCF, VEGF) were observed at higher flow rates.
• No significant differences in secreted protein levels (bFGF, VEGF, TGF-beta) were detected at any condition.

Conclusions:

• Intramyocardial administration of hMSCs via transcatheter techniques is unlikely to compromise cell replication or secretion of key factors.
• The study suggests that needle transit effects are transient and do not impede the therapeutic mechanisms of hMSCs in cardiac repair.
• hMSC functionality relevant to cardiac tissue repair and regeneration is preserved following narrow-gauge needle injection.